TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06161805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. \[1\].

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 hour infusion with saline (NaCl 0.9%)
Study: NCT04672356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI939
Description: IBI939 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI939
Description: IBI939 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab injection
Study: NCT05216224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450
Description: Oral, small molecule MK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo tablet manufactured to match ATI-450 in appearance
Study: NCT05764239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1934v1
Description: SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1934v1
Description: SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1934v1
Description: SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
Study: NCT05088967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: R2PD d1 IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200mg d1 IV every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sintilimab
Description: 200mg d1 IV every 3 weeks
Study: NCT04712474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home decluttering practice
Description: The in-home decluttering intervention comprises 10, 1.5-hour home-visits over the course of 10 weeks.~These home visits are personalized, goal-oriented and focused on decluttering. They include 1) a brief check-in, 2) guided unclutter time 3) a reflective period during which participants share their thoughts and objectives for the coming week, and 4) homework assignments.
Study: NCT04857112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose MT-1303
Description: MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose MT-1303
Description: MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, QD (Day 1-85)
Study: NCT06479681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer recovery coaching (PRC)
Description: The RC-Link peer recovery coaching intervention provides participants with an introduction to an RC-Link coach during their hospitalization. The RC-Link coach delivers coaching and support services for a 6-month period using a standardized PRC Checklist. During the baseline visit, the RC-Link coach first develops a personalized recovery plan with the participant that emphasizes multiple pathways to recovery, including different types of mutual aid groups, counseling, and alternative recovery tools. The approach empowers the participant with an actionable recovery plan that can be initiated upon discharge, but the plan can be modified as changes arise. After the initial baseline encounter, the RC-Link coach initiates phone, virtual, and/or in-person contact with the participant a minimum of twice weekly using the PRC Checklist to standardize service delivery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention (SBIRT)
Description: The control will receive a brief intervention, usual care (a referral list), contact information for the study team and hospital case management, and a follow-up contact at the end of the study period. The brief intervention entails (a) using motivational interviewing to gauge the individual's perspective of drinking, how it influences their life, and readiness for change; (b) provide information about the risks of hazardous drinking and potential ways to reduce drinking; (c) elicit their feedback; listen to their concerns; offer encouragement; encourage them to establish goals for behavior change; and (d) provide resources for change (e.g., the referral list). The referral list includes contact information for no-cost peer recovery coach through FAVOR that the participant could choose to call via self-referral. Thus, control participants are able to be linked to PRC, but they must initiate the call and initial visit outside the hospital setting.
Study: NCT05593211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kronos Electrocautery Device
Description: The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition
Study: NCT05913284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
Study: NCT05627752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 40 MG
Description: Adding Enzalutamide to Docetaxel chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection
Description: Docetaxel chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel injection
Description: Docetaxel chemotherapy
Study: NCT06020196

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical rectus sheath block
Description: Local anaesthetic will be administered into the rectus sheath space by the surgeon, towards the end of the operation, at the time of closure of the anterior abdominal wall (before the closure of peritoneum)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subdermal local anaesthetic infiltration
Description: After closure of the subcutaneous fat, the edges of the skin become more stable; subdermal Infiltration with moving needle technique was done to optimize distribution of the local anesthetic solution
Study: NCT06239779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The education intervention involves a brief PowerPoint presentation delivered by a physician, covering an overview of fibromyalgia, coping strategies, and the potential impact of smart phone addiction on fibromyalgia.
Study: NCT06283667

Intervention type: DRUG
Intervention: Semaglutide
Description: Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
Study: NCT05554926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0117
Description: 2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117
Study: NCT05840822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Nightly capsules prior to bed containing 0mg (placebo), 75mg cannabidiol or 150mg cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Nightly capsules prior to bed containing 0mg (placebo), 75mg cannabidiol or 150mg cannabidiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol
Description: Nightly capsules prior to bed containing 0mg (placebo), 75mg cannabidiol or 150mg cannabidiol
Study: NCT06061224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early mobilization (physical therapy)
Description: The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early mobilization (physical therapy)
Description: The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department
Study: NCT05687838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music medicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music medicine
Study: NCT05479838

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Coronary angiography will be performed via the femoral or radial artery, and primary PCI will be performed using standard guide catheters, guide wires, balloon catheters, and stents according to current guidelines. All PCI interventions performed by invasive cardiologists. The primary PCI type and contrast amount will be decided by the medical team. All patients will be treated by administering non-ionic, monomeric, low-osmolar iodinated iohexol as an intravascular contrast agent .
Study: NCT04667715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exablate BBBD
Description: Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators
Study: NCT05832944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided hyomental distance
Description: measuring the hyomental distance by ultrasound guidance
Study: NCT05056675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
Study: NCT06223841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAP0971
Description: IAP0971 should be subcutaneous injected，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAP0971
Description: IAP0971 should be subcutaneous injected，q3w
Study: NCT05187000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: individualized repetitive transcranial magnetic stimulation
Description: During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
Study: NCT05079906

Intervention type: DEVICE
Group type: OTHER
Intervention: Fractional Flow Reserve (FFR)
Description: Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Fractional Flow Reserve (FFR)
Description: Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.

Intervention type: DEVICE
Group type: OTHER
Intervention: High Definition Intravascular Ultrasound (HD-IVUS)
Description: High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
Study: NCT05210374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m\^2/day) Level~0 (225mg/m\^2/day) Level 1 (300mg/m\^2/day), max~480mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Gluconate
Description: To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin (Doxil)
Description: To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles
Study: NCT04438330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nickel sulfate hexahydrate
Description: Patch test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nickel sulfate hexahydrate
Description: Patch test
Study: NCT06271083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with response prevention
Description: The central component of the intervention will be ERP. During the treatment, participants will receive information about tics and how to work with ERP. Continuously throughout the treatment patients will work with exposing themselves to situations that trigger their premonitory urges and practice suppressing their tics. They will learn different strategies to provoke their premonitory urges to make suppression of their tics more challenging and gradually increase the time they can suppress the tics. A central tool in the treatment will be the Ticstimer, a worksheet where patients will continuously record their ERP practice, and the time they manage to suppress tics. The patients will be encouraged to work with the Ticstimer daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief psychoeducation with general psychological support
Description: Participants who are randomized to the control group will receive access to brief psychoeducational content in the platform in combination with general psychological support from a therapist. No active BT components (BT, Habit Reversal Training, applied relaxation) are provided to the participants in the control group. The therapists will welcome the patients to the treatment, encourage them to engage in the treatment content and reach out to the therapist if they have any questions. Thereafter, the therapists will only reply to the patients' messages without taking any contact initiative themselves (unless there is an indication of severe deterioration or severe depressive symptoms or suicidal ideation requiring medical attention)
Study: NCT04675905

Intervention type: OTHER
Intervention: no intervention (cohort study)
Description: Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged \>= 65 years

Intervention type: OTHER
Intervention: no intervention (cohort study)
Description: Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged \>= 65 years
Study: NCT05436106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Intervention Approach
Description: This is an adaptive intervention approach with 7 module-based sessions selected on the basis of post-session assessments of acceptability and satisfaction;~1. weekly group sessions will be co-led by a community member with expertise in working with transgender women and a public health nurse,~2. supplemental educational content will be available for individual consumption via an online portal or application (and tracked via participant click counts), and~3. additional social resources will be available through the online portal or app.
Study: NCT05720117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYX-201
Description: Intravenous (IV) infusion
Study: NCT06240377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided percutaneous neuromodulation (NMP)
Description: EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate.
Study: NCT06198413

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX102 subretinal injection
Description: LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX102 subretinal injection
Description: LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX102 subretinal injection
Description: LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
Study: NCT05426447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention of reduced protein intake
Description: 6-wk dietary intervention of reduced protein intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention of normal protein intake
Description: 6-wk dietary intervention of normal protein intake
Study: NCT05985902

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stabilization Exercises
Description: Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus ma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercises
Description: In the Schroth exercise training, there are 3-dimensional exercises that include the principles of axial reach, deflection, derotation, rotational breathing and stabilization.
Study: NCT04926441

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Levels and Mental Well-Being assessment
Description: At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.